Evidence map›Paper›PMID 40364451›Full record

ArticleHistopathology2025

Current practices in prostate pathology reporting: results from a survey of genitourinary and general pathologists.

Mahra Nourbakshs, Liping Du, Andres M Acosta, Reza Alaghehbandan, Ali Amin, Mahul B Amin, Manju Aron, Daniel Berney, Fadi Brimo, Emily Chan and 41 more

Abstract read
In one paragraph

Article in Histopathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

51 authors.

Mahra NourbakshsNeoGenomics Laboratories, Aliso Viejo, CA, USA.
Liping DuDepartment of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID https://orcid.org/0000-0003-4926-2135
Andres M AcostaDepartment of Pathology, Indiana University Health, Indianapolis, IN, USA.ORCID https://orcid.org/0000-0001-8817-6331
Reza AlaghehbandanDepartment of Pathology, Cleveland Clinic, Cleveland, OH, USA.ORCID https://orcid.org/0000-0002-6708-5032
Ali AminDepartment of Pathology, Alpert Medical School of Brown University, Providence, RI, USA.ORCID https://orcid.org/0000-0003-4798-0424
Mahul B AminDepartment of Pathology and Laboratory Medicine, University of Tennessee Health Science, Memphis, TN, USA.ORCID https://orcid.org/0000-0001-5943-3634
Manju AronDepartment of Pathology, Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA.ORCID https://orcid.org/0000-0003-1577-3586
Daniel BerneyCentre of Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute, Queen Mary University of London, London, UK.ORCID https://orcid.org/0000-0001-5474-8696
Fadi BrimoDepartment of Pathology, McGill University Health Center, Montréal, Quebec, Canada.ORCID https://orcid.org/0000-0002-7589-0453
Emily ChanDepartment of Pathology, Stanford Medical Center, Stanford, CA, USA.ORCID https://orcid.org/0000-0002-7290-4004
Liang ChengDepartment of Pathology, Alpert Medical School of Brown University, Providence, RI, USA.
Maurizio ColecchiaDepartment of Pathology, Pathology Unit, Vita-Salute San Raffaele University, Milan, Italy.ORCID https://orcid.org/0000-0003-1914-0743
Jasreman DhillonDepartment of Pathology, Moffitt Cancer Center, Tampa, FL, USA.ORCID https://orcid.org/0000-0001-6785-3487
Michelle R DownesLaboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.ORCID https://orcid.org/0000-0002-4528-3724
Andrew J EvansLaboratory Medicine, Mackenzie Health, Toronto, Ontario, Canada.
Lara R HarikDepartment of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, USA.
Oudai HassanDepartment of Surgical Pathology, Henry Ford Cancer Institute, Henry Ford Health, Detroit, MI, USA.
Aiman HaiderDepartment of Pathology, University College London Hospitals NHS Foundation Trust, London, UK.
Peter A HumphreyYale School of Medicine, New Haven, CT, USA.
Shilpy JhaDepartment of Pathology, Advanced Medical and Research Institute, Bhubaneswar, India.
Shivani KandukuriDepartment of Pathology, Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA.
Chia-Sui Sunny KaoDepartment of Pathology, Cleveland Clinic, Cleveland, OH, USA.ORCID https://orcid.org/0000-0001-6609-2567
Seema KaushalDepartment of Pathology, All India Institute of Medical Sciences, New Delhi, India.ORCID https://orcid.org/0000-0002-6190-5909
Francesca KhaniDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA.ORCID https://orcid.org/0000-0001-7238-8604
Oleksandr N KryvenkoMiller School of Medicine, University of Miami, Miami, FL, USA.ORCID https://orcid.org/0000-0001-5731-1748
Charlotte KweldamDepartment of Pathology, Maasstad Hospital, Rotterdam, The Netherlands.ORCID https://orcid.org/0000-0002-1581-9612
Priti LalDepartment of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.ORCID https://orcid.org/0000-0002-7308-0190
Anandi LoboDepartment of Pathology, Kapoor Centre of Urology and Pathology, Raipur, India.ORCID https://orcid.org/0000-0002-3051-8009
Fiona MacleanDepartment of Pathology, Douglass Hanly Moir Pathology, Sydney, NSW, Australia.ORCID https://orcid.org/0000-0002-6468-2368
Cristina Magi-GalluzziDepartment of Pathology, The University of Alabama at Birmingham, Birmingham, AL, USA.ORCID https://orcid.org/0000-0003-1219-3797
Rohit MehraDepartment of Pathology, University of Michigan, Ann Arbor, MI, USA.ORCID https://orcid.org/0000-0002-6955-8884
Hiroshi MiyamotoDepartment of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY, USA.ORCID https://orcid.org/0000-0001-7610-7769
Sambit K MohantyDepartment of Pathology, Advanced Medical and Research Institute, Bhubaneswar, India.ORCID https://orcid.org/0000-0001-5094-2424
Rodolfo MontironiMolecular Medicine and Cell Therapy Foundation, c/o Polytechnic University of the Marche Region, Ancona, Italy.ORCID https://orcid.org/0000-0003-3938-610X
Gabriella NesiDepartment of Health Sciences, University of Florence, Florence, Italy.ORCID https://orcid.org/0000-0002-2614-944X
George Jabboure NettoDepartment of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.ORCID https://orcid.org/0000-0003-3915-9134
Jane K NguyenDepartment of Pathology, Cleveland Clinic, Cleveland, OH, USA.ORCID https://orcid.org/0000-0002-1653-4942
Maya NouriehDepartment of Diagnostic and Theranostic Medicine, Versailles Saint Quentin University UVSQ, Institut CURIE, Saint-Cloud, France.ORCID https://orcid.org/0000-0002-4670-6477
Adeboye O OsunkoyaDepartment of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, USA.ORCID https://orcid.org/0000-0001-5712-8134
Gladell P PanerDepartment of Pathology and Surgery (Urology), The University of Chicago, Chicago, IL, USA.
Ankur R SangoiDepartment of Pathology, Stanford Medical Center, Stanford, CA, USA.ORCID https://orcid.org/0009-0007-7233-2361
Rajal B ShahDepartment of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, USA.ORCID https://orcid.org/0000-0003-0820-6823
John R SrigleyLaboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.
Maria TretiakovaDepartment of Pathology, University of Washington, Seattle, WA, USA.ORCID https://orcid.org/0000-0002-0819-9638
Patricia TroncosoDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID https://orcid.org/0000-0002-8241-1430
Kiril TrpkovDepartment of Pathology and Laboratory Medicine, University of Calgary, Calgary, AB, Canada.ORCID https://orcid.org/0000-0003-3142-8846
Theodorus H Van Der KwastUniversity Health Network, University of Toronto, Toronto, ON, Canada.ORCID https://orcid.org/0000-0001-8640-5786
Miao ZhangDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Debra L ZyngerDepartment of Pathology, The Ohio State University Wexner Medical Center, Columbus, OH, USA.ORCID https://orcid.org/0000-0003-1038-5699
Sean R WilliamsonDepartment of Pathology, Cleveland Clinic, Cleveland, OH, USA.ORCID https://orcid.org/0000-0002-3898-1460
Giovanna A GiannicoDepartment of Pathology, Indiana University Health, Indianapolis, IN, USA.ORCID https://orcid.org/0000-0002-0326-3207

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsStandardizing pathology reporting protocols through peer consensus review is critical for the best quality of care metrics. Reporting heterogeneity due to discrepancies among professional societies and practice patterns may lead to heterogeneous management and treatment approaches. This issue prompted a multi-institutional survey of pathologists to address potential similarities or differences in trends and practice patterns in prostate pathology reporting worldwide. METHODS AND

resultsA REDCap survey was distributed among 175 pathologists worldwide, recruited through invitations and social media. The response rate among invited pathologists was 83%. The practice locations were as follows: North America (USA, Canada, and Mexico, 62%), Europe (17%), Australia/New Zealand (3%), Central/South America (2%), Asia (13%), and Africa (2%). Most pathologists practiced for <5 years (28%). A genitourinary (GU) pathology fellowship was completed by 37%, 58% practiced in a subspecialized setting, and 43% in academia. Reporting includes (63%) or subtracts (37%) intervening benign tissue. Both Gleason score and Grade Groups (GG)s were reported by 96% of responders, whereas 94% report percent pattern 4 (%4). Aggregate grading and volume estimation in undesignated cores with different grades in the same jar are reported by 73% and 54% for systematic biopsies, and 83% and 62% for targeted biopsies, respectively. Cribriform morphology was reported by 81%. For presumed intraductal carcinoma (IDC), 89% use basal cell markers when isolated (iIDC), 82% with GG1 cancer, and 37% with ≥GG2. iIDC or IDC associated with GG1 or with ≥GG2 was not graded by 90%, 78%, and 70%, respectively. In radical prostatectomies, 90% report %4, but only 53% report it if the overall grade is ≥7. A tumour with Gleason 3 + 3 = 6 and <5% pattern 4 was graded as GG2 by 64%. A <5% cutoff for defining tertiary pattern was used by 74%, and 80% report >5% pattern 4 or 5 as a secondary pattern. Grading was assigned based on the dominant nodule by 59%. Finally, reporting practices were significantly associated with demographic characteristics.

conclusionsAlthough most issues are agreed upon, significant discordance is identified among societies and pathologists in different practice settings. We hope this survey will serve as the basis for future studies and new collaborative approaches to more standardized reporting practices.

Indexed as

Pathology, ClinicalPractice Patterns, Physicians'ProstateProstatic NeoplasmsHumansMaleNeoplasm GradingPathologistsSurveys and Questionnairesprostateprostate cancerreportingsurvey

Identifiers

PMID40364451
PMCPMC12232231

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.